GW Pharmaceuticals Plc (GWP)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013543)
◆英語タイトル:GW Pharmaceuticals Plc (GWP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013543
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:54
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
GW Pharmaceuticals plc (GW Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes innovative therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing other products that are focused at treating Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy, glioma, schizophrenia, autism among others. The company along with its subsidiaries operates in the US, England and Wales. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc (GWP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
GW Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 10
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Mentor Capital Invests USD1 Million in GW Pharma 12
Partnerships 13
GW Pharma Enters into Research Agreement with New South Wales 13
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14
Licensing Agreements 15
GW Pharma Terminates License Agreement With Novartis Pharma 15
Equity Offering 17
GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 17
GW Pharma Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of ADSs for USD206 Million 19
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 21
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 23
GW Pharma Announces Partial Exercise Of Underwriter’s Option Of American Depository Shares For US$33 Million 25
Acquisition 27
GW Pharma May Sell Itself 27
GW Pharmaceuticals Plc – Key Competitors 28
GW Pharmaceuticals Plc – Key Employees 29
GW Pharmaceuticals Plc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results 31
May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress 33
Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress 35
Dec 05, 2016: GW Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress 36
Aug 09, 2016: GW Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Progress 37
May 05, 2016: GW Pharmaceuticals Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress 38
Feb 10, 2016: GW Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Progress 39
Corporate Communications 40
May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments 40
Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director – UK 41
Government and Public Interest 42
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 42
Product News 43
02/25/2016: Edison Issues ADR Update on GW Pharmaceuticals 43
01/20/2016: State Health Department Announces Compassionate Use Studies of Cannabidiol for Children and Young Adults With Treatment-resistant Epilepsy 44
Product Approvals 45
Apr 21, 2016: GW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous Sclerosis Complex 45
Clinical Trials 46
Sep 26, 2016: GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 46
Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 48
Jun 21, 2016: GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) 50
Apr 11, 2016: GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex 51
Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol) 52
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GW Pharmaceuticals Plc, Deals By Therapy Area, 2011 to YTD 2017 9
GW Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 10
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Mentor Capital Invests USD1 Million in GW Pharma 12
GW Pharma Enters into Research Agreement with New South Wales 13
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14
GW Pharma Terminates License Agreement With Novartis Pharma 15
GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 17
GW Pharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD206 Million 19
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 21
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 23
GW Pharma Announces Partial Exercise Of Underwriter’s Option Of American Depository Shares For US$33 Million 25
GW Pharma May Sell Itself 27
GW Pharmaceuticals Plc, Key Competitors 28
GW Pharmaceuticals Plc, Key Employees 29
GW Pharmaceuticals Plc, Other Locations 30
GW Pharmaceuticals Plc, Subsidiaries 30

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ GW Pharmaceuticals Plc (GWP)-製薬・医療分野:企業M&A・提携分析(GW Pharmaceuticals Plc (GWP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆